1Pai-Seong Lim, Yau-Huei Wei, York-Leng Yu, et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant, 1999, 14: 2680-2687.
2Owen WF Jr. Optimizing the use of parenteral iron in endstage renal disease patients: focus on issues of infection and cardiovascular disease. Am J Kidney Dis. 1999,34(4 Suppl2):S1-S2.
3Pupim LB, Himmelfarb J, McMonagle E, et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int, 2004, 65: 2371-2379.
4Girndt M, Kaul H, Sester U, et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney lnt, 2002, 62:949-955.
5Barnes PJ, Karin M. Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997, 336: 1066-1071.
